Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07362875 · ClinicalTrials.gov registry record
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
A clinical trial of Myotonic Dystrophy, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT07362875: Recruiting study of Myotonic Dystrophy, sponsored by Wake Forest University Health Sciences.
NCT07362875 is a study of Myotonic Dystrophy that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 75 participants, below the 847-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07362875, a study of Myotonic Dystrophy, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatments are available that alter the course of the disease, but ongoing clinical trials are underway.
Primary Outcome
Contractile muscle volume (CMV, cm3) of individual muscles and the total CMV within the thigh (anterior, medial, posterior) and calf (anterior, lateral, posterior) compartments
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2029-05 |
What NCT07362875 shows while recruiting
NCT07362875 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 847-participant average among 9 other Myotonic Dystrophy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Myotonic Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT07362875 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT07362875 about?
NCT07362875 is a clinical study titled "Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy". Myotonic dystrophy (dystrophia myotonica; DM), the most prevalent form of muscular dystrophy in adults, is characterized by progressive myopathy, myotonia, and multi-systemic involvement. DM causes severe disability and profoundly affects the patient's quality of life. Currently, no effective treatm...
What is the current status of trial NCT07362875?
This trial is currently recruiting. The enrollment target is 75 participants. The study started on 2025-05-15. Estimated completion is 2029-05.
What conditions does trial NCT07362875 study?
This clinical trial studies the following conditions: Myotonic Dystrophy.
Who is sponsoring clinical trial NCT07362875?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07362875 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myotonic Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07362875's enrollment target sits among peer trials
75 7th of 9 higher than 3 of 9 other Myotonic Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myotonic Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1
RECRUITING · Phase 1
-
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
RECRUITING
-
Biomarker Development for Muscular Dystrophies
RECRUITING
-
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
RECRUITING
-
Extracellular RNA Biomarkers of Myotonic Dystrophy
RECRUITING
-
Myotonic Dystrophy Family Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI